Geometry Dash APK Hill Climb Racing APK
65.5 F
New York
Saturday, September 30, 2023

The Forecast Just Changed on Cytokinetics Incorporated (NASDAQ:CYTK)

Must read

Cytokinetics Incorporated (CYTK) shares are trading at higher $18.00 and the avg recommendation for the stock is Moderate Buy, while the current analyst price target stands at $24.44.

To add more color to this target, the company’s high over the last year is $30.14 and the low is $8.00. Over the last 52 weeks, CYTK is up 84.05% while the S&P 500 is up 18.49%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In the last quarter, CYTK reported a profit of $36.5 million. Cytokinetics Incorporated also saw revenues increase to $41.69 million. In addition, CYTK has free cash flow of -$47.7 million as of 09-2020. The company’s EBITDA came in at $5.72 million which compares well with its peers.

CYTK Return on Assets is -36.40%. All told, it is clear that, CYTK needs to be on your watchlist.

Find out when CYTK reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. CYTK has a short ratio of 5.39 and outstanding shares of 68.28M.

Company Outlook

CYTK has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 1.0 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -1.91. Cytokinetics Incorporated CYTK also noted assets of $474.11 million at the end of the last quarter. Investors should also keep an eye on sector updates as CYTK has historically followed its peers on positive news.

All told, Cytokinetics Incorporated CYTK has strung together solid data and demonstrated underlying fundamentals. At its current valuation, CYTK represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

Cytokinetics Incorporated CYTK is now commanding a market cap of 1.23B and a float of 63.85M. CYTK is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of CYTK stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in CYTK, either long or short, and we have not been compensated for this article.

Latest article